According to a report, Walgreens is reportedly working with advisers to conduct preliminary discussions with prospective bidders for the unit, worth about $8.78 billion.
The collaboration will offer people an opportunity to learn about and potentially participate in a Phase III clinical trial within Walgreens pharmacies.
Walgreens Specialty Pharmacy expands access to care for patients with complex, chronic conditions and enables partnerships that drive profitability for the retailer's pharmacy business.